Gennex lab Share Price Target Tomorrow 2024 To 2030- Market Overview, Financials

Gennex Laboratories Ltd is a pharmaceutical company specializing in the production of Active Pharmaceutical Ingredients (APIs) and intermediates. With a strong focus on quality, the company caters to both domestic and international markets, serving industries such as healthcare and medicine. Gennex Lab Share Price on BOM as of 25 November 2024 is 19.47 INR. Here will provide you more details on Gennex Lab Share Price Target 2024, 2025, 2026 to 2030.

Gennex Laboratories Ltd: Market Overview

• Open Price: ₹19.21
• High Price: ₹19.86
• Low Price: ₹19.01
• Previous Close: ₹19.21
• Volume: ₹551,945
• Value (Lacs): ₹107.46
• VWAP: ₹19.51
• UC Limit: ₹20.17
• LC Limit: ₹18.25
• P/E ratio: 26.30
• Div yield: N/A
• 52-wk high: ₹29.00
• 52-wk low: ₹13.25
• Mkt cap: ₹442.84Cr
• Face Value: ₹1

Gennex Laboratories Ltd Competitors

Here are four competitor companies of Gennex Laboratories Ltd, along with their approximate market capitalizations:

1. Aarti Drugs Ltd – ₹6,500 crore
2. Granules India Ltd – ₹8,600 crore
3. Laurus Labs Ltd – ₹21,000 crore
4. Divi’s Laboratories Ltd – ₹90,000 crore

Gennex lab Share Price Chart

Gennex lab Share Price Target Tomorrow 2024 To 2030

Gennex lab Share Price Target 2024

Gennex lab share price target 2024 Expected target could be ₹30. Here are three detailed factors that could affect the growth of Gennex Laboratories Ltd for its share price target in 2024:

1. Expansion in API Demand: The increasing global demand for Active Pharmaceutical Ingredients (APIs), especially post-pandemic, presents significant growth opportunities. Gennex’s focus on cost-effective and high-quality API manufacturing can enhance its market share, particularly in export-driven markets where generic drug manufacturing is on the rise.
2. Regulatory Approvals and Compliance: Adherence to global quality standards and obtaining certifications from agencies like the USFDA or EU regulators can unlock new markets. Meeting regulatory requirements efficiently will be crucial to expanding its international footprint and improving investor confidence.

3. R&D and Product Diversification: Continued investment in research and development to create innovative APIs and intermediates will be a key growth driver. Diversifying into high-margin therapeutic segments, such as oncology or specialty drugs, could provide significant long-term revenue streams.

Gennex lab Share Price Target 2025

Gennex lab share price target 2025 Expected target could be ₹33. Here are three detailed factors that could influence Gennex Laboratories Ltd’s growth for its share price target in 2025:

1. Strengthening Export Market Presence: Gennex has opportunities to capitalize on the increasing demand for APIs in regulated markets such as the US and Europe. Strengthening its supply chain, maintaining competitive pricing, and leveraging its compliance with global standards will be critical for boosting its export revenues.
2. Strategic Collaborations and Partnerships: Forming partnerships with larger pharmaceutical companies or generic drug manufacturers can enhance its market reach. These collaborations could lead to long-term supply agreements, ensuring stable revenue streams and investor confidence.

3. Technological Upgradation and Cost Efficiency: Investing in advanced manufacturing technologies can improve production efficiency and reduce costs. By focusing on sustainable practices and green chemistry, Gennex could gain an edge in the competitive pharma industry, attracting ESG-conscious investors and customers.

Gennex lab Share Price Target 2030

Gennex lab share price target 2030 Expected target could be ₹48. Here are three detailed risks and challenges for Gennex Laboratories Ltd as it aims for its share price target by 2030:

1. Regulatory and Compliance Risks: Operating in the pharmaceutical sector, Gennex faces stringent global regulatory requirements. Any delay or failure in securing certifications or meeting quality standards, especially for exports, could hinder market access and tarnish its reputation.
2. Market Competition and Price Pressures: Increasing competition from both established players and new entrants in the API segment may lead to price wars, potentially squeezing profit margins and reducing market share.

3. Raw Material Dependency and Cost Fluctuations: APIs rely heavily on raw materials, often imported. Volatility in raw material prices or disruptions in supply chains due to geopolitical issues, trade restrictions, or environmental regulations could negatively impact production costs and profitability.

Shareholding Pattern For Gennex Laboratories Ltd

• Promoters: 18.42%
• Public: 81.58%

Gennex Laboratories Ltd Financials

Read Also:- Quasar India Share Price Target Tomorrow 2024 To 2030 and More Details